0001140361-19-015573.txt : 20190826 0001140361-19-015573.hdr.sgml : 20190826 20190826083058 ACCESSION NUMBER: 0001140361-19-015573 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190825 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190826 DATE AS OF CHANGE: 20190826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 191050610 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 form8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2019

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of Incorporation)
  
001-01136
(Commission File Number)
  
22-0790350
(IRS Employer Identification Number)

430 East 29th Street, 14th Floor
New York, New York, 10016
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
 BMY25
New York Stock Exchange
1.750% Notes due 2035
 BMY35
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01          Other Events.

On August 26, 2019, Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) issued a press release (the “Press Release”) providing an update on Bristol-Myers Squibb’s pending merger (the “Merger”) with Celgene Corporation (“Celgene”). In furtherance of Bristol-Myers Squibb’s previously announced plan to divest OTEZLA® (apremilast), on August 25, 2019, Celgene and Amgen Inc. (“Amgen”), entered into an Asset Purchase Agreement (the “Purchase Agreement”). The Purchase Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Amgen will acquire OTEZLA for $13.4 billion in cash. The closing of the acquisition covered by the Purchase Agreement is subject, among other things, to the issuance by the Federal Trade Commission (“FTC”) of a consent order requiring Celgene to divest OTEZLA to Amgen and the closing of the Merger. The terms of the Purchase Agreement remain subject to FTC approval.

Pursuant to the terms of the Purchase Agreement, on August 25, 2019, Bristol-Myers Squibb entered into an Irrevocable Guarantee with Amgen (the “Guarantee”). The Guarantee provides, among other things, that on the terms and subject to the conditions therein, Bristol-Myers Squibb will (a) irrevocably and unconditionally guarantee the full payment and performance obligations of Celgene under the Purchase Agreement, with effect from the time of, and subject to and conditioned upon the closing of, the Merger, and (b) agree to comply with certain covenants in the Purchase Agreement.

Bristol-Myers Squibb currently expects to close the Merger by the end of 2019.

A copy of the Press Release is filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety.

Important Information For Investors And Stockholders

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

In connection with the proposed transaction between Bristol-Myers Squibb and Celgene, on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, Bristol Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019, and the special meetings of the stockholders of Bristol-Myers Squibb and Celgene were held on April 12, 2019. INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.  Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by Bristol Myers Squibb are available free of charge on Bristol-Myers Squibb’s internet website at http://www.bms.com under the tab, “Investors” and under the heading “Financial Reporting” and subheading “SEC Filings” or by contacting Bristol-Myers Squibb’s Investor Relations Department through https://www.bms.com/investors/investor-contacts.html. Copies of the documents filed with the SEC by Celgene are available free of charge on Celgene’s internet website at http://www.celgene.com under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products and Bristol-Myers Squibb’s pending acquisition of Celgene. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of the Merger may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; the completion of the OTEZLA divestiture by Celgene does not occur on the anticipated timing; the combined company will have substantial indebtedness following the completion of the Merger; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Merger; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Merger has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.

Forward-looking statements in this communication should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this communication are made only as of the date of this document and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Item 9.01          Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
   
99.1
  
Press Release of Bristol-Myers Squibb Company, dated August 26, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
  
Description
   
 
Press Release of Bristol-Myers Squibb Company, dated August 26, 2019.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
     
Dated: August 26, 2019
By:
/s/ Katherine R. Kelly
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary


EX-99.1 2 ex99_1.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Exhibit 99.1

FOR IMMEDIATE RELEASE

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger

Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019

NEW YORK, August 26, 2019 – Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash. Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for the Company’s pending merger with Celgene. The closing of the acquisition covered by the agreement with Amgen is contingent on Bristol-Myers Squibb and Celgene entering into a consent decree with the Federal Trade Commission (FTC) in connection with their pending merger, the closing of the pending merger, and the satisfaction of other customary closing conditions.

“This agreement represents an important step toward completing our pending merger with Celgene. It also demonstrates the tremendous achievement of the Celgene team in establishing OTEZLA as an important medicine for patients with psoriasis, psoriatic arthritis and Behçet’s Disease,” said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. “Together with the OTEZLA team, Amgen has the capabilities and infrastructure to continue to support this important medicine and ensure a seamless transition for patients and healthcare providers.”

Bristol-Myers Squibb now expects the pending merger with Celgene to close by the end of 2019.

Divestiture Terms

Under the terms of the agreement and subject to the closing conditions, Amgen will acquire OTEZLA and related intellectual property, including any patents that primarily cover apremilast, as well as other assets and liabilities related to OTEZLA. The agreement includes the transfer of Celgene employees primarily dedicated to OTEZLA.

Use of Proceeds and Capital Allocation

Bristol-Myers Squibb plans to prioritize the use of proceeds from the OTEZLA divestiture for debt reduction.

In the context of its overall approach to capital allocation, Bristol-Myers Squibb plans to focus on de-leveraging in the near term to maintain strong investment grade credit ratings and less than 1.5x debt/EBITDA by 2023. Beyond that, Bristol-Myers Squibb’s strategic approach to capital allocation remains unchanged with future business development and sourcing external innovation a priority, while continuing to plan for annual dividend increases and disciplined employment of share repurchases.

Today Bristol-Myers Squibb also announced that it is increasing its previously planned $5 billion accelerated share repurchase to $7 billion. The share repurchase will be executed following closing of the pending Bristol-Myers Squibb merger with Celgene, subject to Board approval. The additional authorization is based on strong business trends across both Bristol-Myers Squibb and Celgene, encouraging clinical developments across the pipeline of both companies and increased visibility into the closing of the pending merger with Celgene.

Advisors

Morgan Stanley & Co. LLC is serving as financial advisor to Bristol-Myers Squibb, and Kirkland & Ellis LLP is serving as Bristol-Myers Squibb’s legal counsel regarding the divestiture. Arnold & Porter Kaye Scholer LLP is also acting as legal counsel on antitrust matters.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products and Bristol-Myers Squibb Company’s (“Bristol-Myers Squibb”) pending acquisition of Celgene Corporation (“Celgene”). These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on historical performance and current expectations and projections about Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond Bristol-Myers Squibb’s and Celgene’s control and could cause Bristol-Myers Squibb’s and Celgene’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to, the completion of Bristol-Myers Squibb’s pending acquisition of Celgene ( the “Merger”) may not occur on the anticipated terms and timing or at all; a condition to the closing of the Merger may not be satisfied; the completion of the OTEZLA divestiture by Celgene does not occur on the anticipated timing; the combined company will have substantial indebtedness following the completion of the Merger; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the Merger; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the Merger; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the Merger has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No forward-looking statement can be guaranteed.

Forward-looking statements in this communication should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s and Celgene’s respective business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s and Celgene’s respective Annual Reports on Form 10-K for the year ended December 31, 2018, as updated by their subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this communication are made only as of the date of this document and except as otherwise required by applicable law, neither Bristol-Myers Squibb nor Celgene undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts

Investors:
Tim Power
609-252-7509
timothy.power@bms.com

Media:
Priyanka Shah
609-252-7956
Priyanka.Shah1@BMS.com

or

Andy Brimmer / Dan Katcher / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

 EX-101.SCH 3 bmy-20190825.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20190825_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20190825_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Listings [Table] Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Listings [Line Items] Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company Class of Stock [Domain] Class of Stock [Axis] 1.000% Notes due 2025 [Member] 1.750% Notes due 2035 [Member] Common Stock, $0.10 Par Value [Member] EX-101.PRE 6 bmy-20190825_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 form8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2019-08-25 2019-08-25 0000014272 bmy:One000NotesDue2025Member 2019-08-25 2019-08-25 0000014272 bmy:One750NotesDue2035Member 2019-08-25 2019-08-25 0000014272 bmy:CommonStock010ParValueMember 2019-08-25 2019-08-25 false 0000014272 8-K 2019-08-25 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 East 29th Street 14th Floor New York NY 10016 212 546-4000 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information
Aug. 25, 2019
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 25, 2019
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock, $0.10 Par Value [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 4 97 1 false 3 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports form8k.htm bmy-20190825.xsd bmy-20190825_def.xml bmy-20190825_lab.xml bmy-20190825_pre.xml ex99_1.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bmy-20190825_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "bmy-20190825_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmy-20190825_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmy-20190825.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 3, "memberStandard": 0, "nsprefix": "bmy", "nsuri": "http://bms.com/20190825", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20190825to20190825", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20190825to20190825", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "bmy_CommonStock010ParValueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock, $0.10 Par Value [Member]" } } }, "localname": "CommonStock010ParValueMember", "nsuri": "http://bms.com/20190825", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20190825", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20190825", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001140361-19-015573-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-19-015573-xbrl.zip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end